ReviewThe oncologist2023

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.

Milind Javle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.